CharlieeMungerTWITS
Nov 16, 2:11 AM
$CELC The latest reported short interest was 10.30 million shares as of October 30, or 24.29% of the float, up just 0.5% from the prior report. This represents potential short-squeeze fuel, not evidence that a squeeze has begun. No newly verified material REVTORPYK sales acceleration, earnings surprise, analyst revision, or regulatory decision emerged since the previous review. The November 9 FDA acceptance remains the latest significant regulatory development. The next meaningful signals would be a high-volume recovery above
$70–
$73, a decisive close below
$63, or measurable commercial sales acceleration.
0 replies